These cytokine-associated pathways underlie the inflammasomopathies, relopathies, and interferonopathies, respectively (65)
An estimated 8% of Americans currently use GLP-1 medications, and that number is expected to grow as insurance coverage increases.1 There has been a drastic increase in new research and much buzz amongst patients and clinicians around GLP-1s over the past few years, but they are not new to the medical field
It mimics the hormone GLP-1, reducing appetite, prolonging fullness, and potentially increasing energy expenditure
Still, not everyone feels well while taking them
However, dermatologists usually advise shots rather than tablets
Peptide Vials (5 mg vial, 2.4 mg/week target) Each 5 mg vial covers about 2 weekly doses at 2.4 mg/week